%PDF-1.4
1 0 obj
<< /Type /Catalog /Pages 2 0 R >>
endobj
2 0 obj
<< /Type /Pages /Kids [3 0 R] /Count 1 >>
endobj
3 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Contents 4 0 R /Resources << /Font << /F1 5 0 R >> >> >>
endobj
4 0 obj
<< /Length 950 >>
stream
BT
/F1 24 Tf
50 750 Td
(Oncology Drug Development Report 2024) Tj
0 -40 Td
/F1 14 Tf
(Immunotherapy and Targeted Therapy Analysis) Tj
0 -30 Td
/F1 11 Tf
(The oncology market continues to be the fastest-growing) Tj
0 -15 Td
(therapeutic segment with breakthrough innovations in) Tj
0 -15 Td
(immuno-oncology and precision medicine.) Tj
0 -30 Td
/F1 14 Tf
(Key Drug Classes:) Tj
0 -20 Td
/F1 11 Tf
(- PD-1/PD-L1 Inhibitors: Market leader at USD 45B) Tj
0 -15 Td
(- CAR-T Cell Therapies: Rapid growth, 6 approved products) Tj
0 -15 Td
(- ADCs: 12 approved drugs, 100+ in development) Tj
0 -15 Td
(- Bispecific Antibodies: Emerging class with 8 approvals) Tj
0 -30 Td
/F1 14 Tf
(Clinical Pipeline Highlights:) Tj
0 -20 Td
/F1 11 Tf
(- 2,400+ oncology trials in Phase 2/3) Tj
0 -15 Td
(- NSCLC remains most active indication) Tj
0 -15 Td
(- Combination therapies dominate new trials) Tj
0 -15 Td
(- Biomarker-driven trials increased 60%) Tj
0 -30 Td
/F1 14 Tf
(Market Outlook:) Tj
0 -20 Td
/F1 11 Tf
(Global oncology market projected to reach USD 380B by 2028) Tj
ET
endstream
endobj
5 0 obj
<< /Type /Font /Subtype /Type1 /BaseFont /Helvetica >>
endobj
xref
0 6
0000000000 65535 f 
0000000009 00000 n 
0000000058 00000 n 
0000000115 00000 n 
0000000266 00000 n 
0000001268 00000 n 
trailer
<< /Size 6 /Root 1 0 R >>
startxref
1347
%%EOF